Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS (Details)

v3.19.3.a.u2
SIGNIFICANT CONCENTRATIONS (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Distributor
customer
item
Dec. 31, 2018
USD ($)
Distributor
customer
item
Dec. 31, 2017
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 10,111 $ 4,077  
Aclaris      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 1,500    
Sales | Customer concentration risk      
SIGNIFICANT CONCENTRATIONS      
Number of specialty distributors | Distributor 3 3  
Sales | Customer concentration risk | Three specialty distributors      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 74.00% 31.00%  
Sales | Customer concentration risk | Aclaris      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 9.00%    
Sales | Customer concentration risk | Grifols      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 8.00%    
Sales | Customer concentration risk | Celgene      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 6.00%   26.00%
Sales | Customer concentration risk | Kissei      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 3.00% 69.00%  
Sales | Customer concentration risk | BerGenBio      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage     74.00%
Sales | Customer concentration risk | ASD Healthcare and Oncology Supply      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 37.00% 17.00%  
Sales | Customer concentration risk | McKesson Specialty Care Distribution Corporation      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 30.00% 11.00%  
Accounts receivable | Credit concentration risk | Four customers      
SIGNIFICANT CONCENTRATIONS      
Number of customers | customer 4 4  
Accounts receivable | Credit concentration risk | Four customers and one collaboration partner      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage 100.00% 100.00%  
Accounts receivable | Credit concentration risk | One collaboration partner      
SIGNIFICANT CONCENTRATIONS      
Number of collaboration partners | item 1 1